Consistent with experimental evidence that hCCAR2 knockout renders BRCA1-null cells resistant to DNA damaging agents, BRCA1-deficient breast cancer patients with a low hCCAR2 level have a worse prognosis than those with a high hCCAR2 level1. The gene discussed is BRCA1; the disease is breast cancer.